table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2028)
1.4.2 East Asia Market States and Outlook (2023-2028)
1.4.3 Europe Market States and Outlook (2023-2028)
1.4.4 South Asia Market States and Outlook (2023-2028)
1.4.5 Southeast Asia Market States and Outlook (2023-2028)
1.4.6 Middle East Market States and Outlook (2023-2028)
1.4.7 Africa Market States and Outlook (2023-2028)
1.4.8 Oceania Market States and Outlook (2023-2028)
1.4.9 South America Market States and Outlook (2023-2028)
1.5 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Analysis from 2023 to 2028
1.5.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Analysis from 2023 to 2028 by Consumption Volume
1.5.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Size Analysis from 2023 to 2028 by Value
1.5.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Trends Analysis from 2023 to 2028
1.6 COVID-19 Outbreak: Human Immunodeficiency Virus (HIV)-1 Therapeutics Industry Impact
Chapter 2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics (Volume and Value) by Type
2.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Market Share by Type (2017-2022)
2.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Type (2017-2022)
2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics (Volume and Value) by Application
2.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Market Share by Application (2017-2022)
2.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Application (2017-2022)
2.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics (Volume and Value) by Regions
2.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Regions (2017-2022)
4.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
4.10 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
5.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
5.1.1 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
5.2 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
5.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
5.4 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
5.4.1 United States Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
5.4.2 Canada Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
5.4.3 Mexico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 6 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
6.1 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
6.1.1 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
6.2 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
6.3 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
6.4 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
6.4.1 China Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
6.4.2 Japan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
6.4.3 South Korea Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 7 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
7.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
7.1.1 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
7.2 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
7.3 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
7.4 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
7.4.1 Germany Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.2 UK Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.3 France Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.4 Italy Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.5 Russia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.6 Spain Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.7 Netherlands Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.8 Switzerland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
7.4.9 Poland Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 8 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
8.1 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
8.1.1 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
8.2 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
8.3 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
8.4 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
8.4.1 India Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
8.4.2 Pakistan Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
9.1 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
9.1.1 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
9.2 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
9.3 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
9.4 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
9.4.1 Indonesia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.2 Thailand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.3 Singapore Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.4 Malaysia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.5 Philippines Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.6 Vietnam Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
9.4.7 Myanmar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 10 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
10.1 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
10.1.1 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
10.2 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
10.3 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
10.4 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
10.4.1 Turkey Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.3 Iran Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.5 Israel Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.6 Iraq Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.7 Qatar Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.8 Kuwait Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
10.4.9 Oman Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 11 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
11.1 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
11.1.1 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
11.2 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
11.3 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
11.4 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
11.4.1 Nigeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
11.4.2 South Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
11.4.3 Egypt Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
11.4.4 Algeria Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
11.4.5 Morocco Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 12 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
12.1 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
12.2 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
12.3 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
12.4 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption by Top Countries
12.4.1 Australia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
12.4.2 New Zealand Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 13 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis
13.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption and Value Analysis
13.1.1 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Under COVID-19
13.2 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Types
13.3 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Structure by Application
13.4 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume by Major Countries
13.4.1 Brazil Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.2 Argentina Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.3 Columbia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.4 Chile Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.5 Venezuela Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.6 Peru Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
13.4.8 Ecuador Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Human Immunodeficiency Virus (HIV)-1 Therapeutics Business
14.1 AbbVie, Inc.(U.S.)
14.1.1 AbbVie, Inc.(U.S.) Company Profile
14.1.2 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.1.3 AbbVie, Inc.(U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Merck & Co., Inc. (U.S.)
14.2.1 Merck & Co., Inc. (U.S.) Company Profile
14.2.2 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.2.3 Merck & Co., Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Bristol-Myers Squibb Company (U.S.)
14.3.1 Bristol-Myers Squibb Company (U.S.) Company Profile
14.3.2 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.3.3 Bristol-Myers Squibb Company (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Boehringer Ingelheim GmbH (Germany)
14.4.1 Boehringer Ingelheim GmbH (Germany) Company Profile
14.4.2 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.4.3 Boehringer Ingelheim GmbH (Germany) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Genentech, Inc. (U.S.)
14.5.1 Genentech, Inc. (U.S.) Company Profile
14.5.2 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.5.3 Genentech, Inc. (U.S.) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Cipla, Inc. (India)
14.6.1 Cipla, Inc. (India) Company Profile
14.6.2 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Product Specification
14.6.3 Cipla, Inc. (India) Human Immunodeficiency Virus (HIV)-1 Therapeutics Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast (2023-2028)
15.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Price Forecast (2023-2028)
15.1.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume and Growth Rate Forecast (2023-2028)
15.1.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Value and Growth Rate Forecast (2023-2028)
15.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Value and Growth Rate Forecast by Region (2023-2028)
15.2.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume and Growth Rate Forecast by Regions (2023-2028)
15.2.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Value and Growth Rate Forecast by Regions (2023-2028)
15.2.3 North America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.4 East Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.5 Europe Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.6 South Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.7 Southeast Asia Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.8 Middle East Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.9 Africa Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.10 Oceania Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.2.11 South America Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Growth Rate Forecast (2023-2028)
15.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume, Revenue and Price Forecast by Type (2023-2028)
15.3.1 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Forecast by Type (2023-2028)
15.3.2 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Revenue Forecast by Type (2023-2028)
15.3.3 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Price Forecast by Type (2023-2028)
15.4 Global Human Immunodeficiency Virus (HIV)-1 Therapeutics Consumption Volume Forecast by Application (2023-2028)
15.5 Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
